Pharmacyclics Inc (PCYC)

PCYC (NASDAQ:Drugs) EQUITY
$215.93
pos +0.00
+0.00%
Today's Range: 214.01 - 220.79 | PCYC Avg Daily Volume: 1,088,200
Last Update: 02/27/15 - 3:59 PM EST
Volume: 0
YTD Performance: 76.62%
Open: $0.00
Previous Close: $217.82
52 Week Range: $82.51 - $231.09
Oustanding Shares: 76,016,912
Market Cap: 16,558,003,772
6-Month Chart
TheStreet Ratings Grade for PCYC
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 9 10 10
Moderate Buy 0 0 0 0
Hold 8 5 5 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.14 1.71 1.67 1.67
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 198.02
Price Earnings Comparisons:
PCYC Sector Avg. S&P 500
198.02 197.70 26.52
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
54.98% 49.34% 742.49%
GROWTH 12 Mo 3 Yr CAGR
Revenue 180.50 87.63 3.39
Net Income 28.50 -3.45 0.00
EPS 26.80 -2.93 0.00
Earnings for PCYC:
EBITDA 0.13B
Revenue 0.73B
Average Earnings Estimates
Qtr (03/15) Qtr (06/15) FY (12/15) FY (12/16)
Average Estimate $0.08 $-0.59 $0.43 $4.01
Number of Analysts 7 7 10 9
High Estimate $0.25 $0.43 $1.86 $7.96
Low Estimate $-0.21 $-1.36 $-1.24 $0.85
Prior Year $0.23 $-0.49 $1.09 $0.43
Growth Rate (Year over Year) -66.46% -20.99% -60.28% 827.12%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands

bearishPharmacyclics downgraded at Credit Suisse

Feb 27, 2015 | 8:00 AM EST

PCYC was downgraded from Outperform to Neutral, Credit Suisse said. Valuation call, based on takeover speculation and a $233 price target. 

By

Timothy Collins

 | Feb 25, 2015 | 2:11 PM EST

Two stocks that could hurt your portfolio.

bullishPharmacyclics upgraded at Nomura

Feb 19, 2015 | 7:59 AM EST

PCYC was upgraded from Neutral to Buy, Nomura said. $196 price target. Higher CLL demand could drive earnings upside. 

bearishPharmacyclics downgraded at JP Morgan

Feb 19, 2015 | 7:26 AM EST

PCYC was downgraded from Overweight to Neutral, JP Morgan said. $173 price target. Valuation call, as the stock is up 39% year-to-date.

bullishPharmacyclics numbers boosted at JMP

Jan 22, 2015 | 6:41 AM EST

Shares of PCYC now seen reaching $253, according to JMP Securities. Estimates also increased, given the company's new domestic sales guidance. Outperform rating. 

By

Gary Dvorchak

 | Jan 7, 2015 | 10:30 AM EST

It's crucial to avoid being a 'closet indexer'.

bullishPharmacyclics numbers boosted at Nomura

Nov 5, 2014 | 7:01 AM EST

Shares of PCYC now seen reaching $175, according to Nomura. Estimates also upped, given higher expected Imbruvica results. Buy rating. 

By

Jim Cramer

 | Jul 29, 2014 | 4:21 PM EDT

Something worrisome has me fretting more than I have in a while.

bullishPharmacyclics upgraded at Leerink

Jul 29, 2014 | 7:52 AM EDT

PCYC was upgraded from Market Perform to Outperform, Leerink Swann said. $142 price target. Expect that Zydelig and Imbruvica can drive near-term growth. 

bearishPharmacyclics downgraded at RBC

May 27, 2014 | 7:09 AM EDT

PCYC was downgraded from Outperform to Sector Perform, RBC Capital said. $95 price target. Company is facing potential growth headwinds. 

 

Reports on Tuesday. I am getting a little concerned on how the 2015 guidance will come in....
Soz doing some more good stuff on retail today-- I loved the JCP piece.. Remember you can ...
Despite a big upgrade from Credit Suisse(from Neutral to Outperform)FDX is relatively...
The Market Vectors Gold Miners ETF (GDX) chart continues to exhibit characteristics of a c...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.